Article
<i>In Vivo</i> Efficacy of ABHD17 Inhibition Validates the Palmitoylation Cycle as a Therapeutic Target in <i>NRAS</i> -Mutant Cancer
2025-03-21
Abstract excerpt
<h4>SUMMARY</h4> Ras proteins are functionally dependent on one or more lipid modifications. 1,2 The dynamic palmitoylation of N-Ras by DHHC palmitoyl acyltransferases and depalmitoylation by ABHD17 serine hydrolases is essential for the growth of NRAS -mutant acute myeloid leukemia (AML) cells. 3–6 Here we show that ABD778, an in vivo -active ABHD17 inhibitor, selectively reduces the growth of NRAS -mutant...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 07c867d4-fc59-5c6a-8cf6-14129f15501a
- DOI
- 10.1101/2025.03.20.644389
